1 Market Overview
1.1 Venous Thromboembolism Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Venous Thromboembolism Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Heparin
1.2.3 Apixaban
1.2.4 Dabigatran
1.2.5 Rivaroxaban
1.2.6 Edaxaban
1.2.7 Warfarin
1.3 Market Analysis by Application
1.3.1 Overview: Global Venous Thromboembolism Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Venous Thromboembolism Drug Market Size & Forecast
1.4.1 Global Venous Thromboembolism Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Venous Thromboembolism Drug Sales in Volume (2017-2028)
1.4.3 Global Venous Thromboembolism Drug Price (2017-2028)
1.5 Global Venous Thromboembolism Drug Production Capacity Analysis
1.5.1 Global Venous Thromboembolism Drug Total Production Capacity (2017-2028)
1.5.2 Global Venous Thromboembolism Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Venous Thromboembolism Drug Market Drivers
1.6.2 Venous Thromboembolism Drug Market Restraints
1.6.3 Venous Thromboembolism Drug Trends Analysis
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Venous Thromboembolism Drug Product and Services
2.1.4 Bayer Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 BMS
2.2.1 BMS Details
2.2.2 BMS Major Business
2.2.3 BMS Venous Thromboembolism Drug Product and Services
2.2.4 BMS Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Boehringer Ingelheim
2.3.1 Boehringer Ingelheim Details
2.3.2 Boehringer Ingelheim Major Business
2.3.3 Boehringer Ingelheim Venous Thromboembolism Drug Product and Services
2.3.4 Boehringer Ingelheim Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Daiichi Sankyo
2.4.1 Daiichi Sankyo Details
2.4.2 Daiichi Sankyo Major Business
2.4.3 Daiichi Sankyo Venous Thromboembolism Drug Product and Services
2.4.4 Daiichi Sankyo Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 J&J
2.5.1 J&J Details
2.5.2 J&J Major Business
2.5.3 J&J Venous Thromboembolism Drug Product and Services
2.5.4 J&J Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Venous Thromboembolism Drug Product and Services
2.6.4 Sanofi Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Altor Bioscience
2.7.1 Altor Bioscience Details
2.7.2 Altor Bioscience Major Business
2.7.3 Altor Bioscience Venous Thromboembolism Drug Product and Services
2.7.4 Altor Bioscience Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Armetheon
2.8.1 Armetheon Details
2.8.2 Armetheon Major Business
2.8.3 Armetheon Venous Thromboembolism Drug Product and Services
2.8.4 Armetheon Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Aspen Pharma
2.9.1 Aspen Pharma Details
2.9.2 Aspen Pharma Major Business
2.9.3 Aspen Pharma Venous Thromboembolism Drug Product and Services
2.9.4 Aspen Pharma Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 BioInvent
2.10.1 BioInvent Details
2.10.2 BioInvent Major Business
2.10.3 BioInvent Venous Thromboembolism Drug Product and Services
2.10.4 BioInvent Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 eXIthera Pharmaceuticals
2.11.1 eXIthera Pharmaceuticals Details
2.11.2 eXIthera Pharmaceuticals Major Business
2.11.3 eXIthera Pharmaceuticals Venous Thromboembolism Drug Product and Services
2.11.4 eXIthera Pharmaceuticals Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Gamma Therapeutics
2.12.1 Gamma Therapeutics Details
2.12.2 Gamma Therapeutics Major Business
2.12.3 Gamma Therapeutics Venous Thromboembolism Drug Product and Services
2.12.4 Gamma Therapeutics Venous Thromboembolism Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Venous Thromboembolism Drug Breakdown Data by Manufacturer
3.1 Global Venous Thromboembolism Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Venous Thromboembolism Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Venous Thromboembolism Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Venous Thromboembolism Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Venous Thromboembolism Drug Manufacturer Market Share in 2021
3.5 Global Venous Thromboembolism Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Venous Thromboembolism Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Venous Thromboembolism Drug Market Size by Region
4.1.1 Global Venous Thromboembolism Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Venous Thromboembolism Drug Revenue by Region (2017-2028)
4.2 North America Venous Thromboembolism Drug Revenue (2017-2028)
4.3 Europe Venous Thromboembolism Drug Revenue (2017-2028)
4.4 Asia-Pacific Venous Thromboembolism Drug Revenue (2017-2028)
4.5 South America Venous Thromboembolism Drug Revenue (2017-2028)
4.6 Middle East and Africa Venous Thromboembolism Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Venous Thromboembolism Drug Sales in Volume by Type (2017-2028)
5.2 Global Venous Thromboembolism Drug Revenue by Type (2017-2028)
5.3 Global Venous Thromboembolism Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Venous Thromboembolism Drug Sales in Volume by Application (2017-2028)
6.2 Global Venous Thromboembolism Drug Revenue by Application (2017-2028)
6.3 Global Venous Thromboembolism Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Venous Thromboembolism Drug Sales by Type (2017-2028)
7.2 North America Venous Thromboembolism Drug Sales by Application (2017-2028)
7.3 North America Venous Thromboembolism Drug Market Size by Country
7.3.1 North America Venous Thromboembolism Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Venous Thromboembolism Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Venous Thromboembolism Drug Sales by Type (2017-2028)
8.2 Europe Venous Thromboembolism Drug Sales by Application (2017-2028)
8.3 Europe Venous Thromboembolism Drug Market Size by Country
8.3.1 Europe Venous Thromboembolism Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Venous Thromboembolism Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Venous Thromboembolism Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Venous Thromboembolism Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Venous Thromboembolism Drug Market Size by Region
9.3.1 Asia-Pacific Venous Thromboembolism Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Venous Thromboembolism Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Venous Thromboembolism Drug Sales by Type (2017-2028)
10.2 South America Venous Thromboembolism Drug Sales by Application (2017-2028)
10.3 South America Venous Thromboembolism Drug Market Size by Country
10.3.1 South America Venous Thromboembolism Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Venous Thromboembolism Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Venous Thromboembolism Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Venous Thromboembolism Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Venous Thromboembolism Drug Market Size by Country
11.3.1 Middle East & Africa Venous Thromboembolism Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Venous Thromboembolism Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Venous Thromboembolism Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Venous Thromboembolism Drug
12.3 Venous Thromboembolism Drug Production Process
12.4 Venous Thromboembolism Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Venous Thromboembolism Drug Typical Distributors
13.3 Venous Thromboembolism Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
世界の静脈血栓塞栓症治療薬市場2022年：ヘパリン、アピキサバン、ダビガトラン、リバーロキサバン、エダキサバン、ワルファリン |
| 【英語タイトル】Global Venous Thromboembolism Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 | |
 | ・商品コード：GIR22NO19689 ・発行会社（調査会社）：GlobalInfoResearch ・発行日：2022年11月2日（※2025年版があります。お問い合わせください。） ・ページ数：106 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（注文後2-3日） ・調査対象地域：グローバル ・産業分野：医薬品 |
| Single User（1名様閲覧用） | USD3,480 ⇒換算￥528,960 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD5,220 ⇒換算￥793,440 | 見積依頼/購入/質問フォーム |
| Corporate User（同一法人内共有可） | USD6,960 ⇒換算￥1,057,920 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 静脈血栓塞栓症治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の静脈血栓塞栓症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 静脈血栓塞栓症治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・ヘパリン、アピキサバン、ダビガトラン、リバーロキサバン、エダキサバン、ワルファリン 用途別セグメントは次のように区分されます。 ・病院、診療所 世界の静脈血栓塞栓症治療薬市場の主要な市場プレーヤーは以下のとおりです。 ・Bayer、BMS、Boehringer Ingelheim、Daiichi Sankyo、J&J、Sanofi、Altor Bioscience、Armetheon、Aspen Pharma、BioInvent、eXIthera Pharmaceuticals、Gamma Therapeutics 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、静脈血栓塞栓症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な静脈血栓塞栓症治療薬メーカーの企業概要、2019年～2022年までの静脈血栓塞栓症治療薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な静脈血栓塞栓症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別静脈血栓塞栓症治療薬の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの静脈血栓塞栓症治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での静脈血栓塞栓症治療薬市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および静脈血栓塞栓症治療薬の産業チェーンを掲載しています。 ・第13、14、15章では、静脈血栓塞栓症治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 - 静脈血栓塞栓症治療薬の概要 - 種類別分析（2017年vs2021年vs2028年）：ヘパリン、アピキサバン、ダビガトラン、リバーロキサバン、エダキサバン、ワルファリン - 用途別分析（2017年vs2021年vs2028年）：病院、診療所 - 世界の静脈血栓塞栓症治療薬市場規模・予測 - 世界の静脈血栓塞栓症治療薬生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Bayer、BMS、Boehringer Ingelheim、Daiichi Sankyo、J&J、Sanofi、Altor Bioscience、Armetheon、Aspen Pharma、BioInvent、eXIthera Pharmaceuticals、Gamma Therapeutics ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：ヘパリン、アピキサバン、ダビガトラン、リバーロキサバン、エダキサバン、ワルファリン ・用途別分析2017年-2028年：病院、診療所 ・静脈血栓塞栓症治療薬の北米市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・静脈血栓塞栓症治療薬のヨーロッパ市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・静脈血栓塞栓症治療薬のアジア市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・静脈血栓塞栓症治療薬の南米市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・静脈血栓塞栓症治療薬の中東・アフリカ市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Venous Thromboembolism Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Venous Thromboembolism Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Venous Thromboembolism Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Heparin segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Venous Thromboembolism Drug include Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, and J&J, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Venous Thromboembolism Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Heparin
Apixaban
Dabigatran
Rivaroxaban
Edaxaban
Warfarin
Market segment by Application can be divided into
Hospital
Clinic
The key market players for global Venous Thromboembolism Drug market are listed below:
Bayer
BMS
Boehringer Ingelheim
Daiichi Sankyo
J&J
Sanofi
Altor Bioscience
Armetheon
Aspen Pharma
BioInvent
eXIthera Pharmaceuticals
Gamma Therapeutics
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Venous Thromboembolism Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Venous Thromboembolism Drug, with price, sales, revenue and global market share of Venous Thromboembolism Drug from 2019 to 2022.
Chapter 3, the Venous Thromboembolism Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Venous Thromboembolism Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Venous Thromboembolism Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Venous Thromboembolism Drug.
Chapter 13, 14, and 15, to describe Venous Thromboembolism Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
| ★調査レポート[世界の静脈血栓塞栓症治療薬市場2022年：ヘパリン、アピキサバン、ダビガトラン、リバーロキサバン、エダキサバン、ワルファリン] (コード：GIR22NO19689)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の静脈血栓塞栓症治療薬市場2022年：ヘパリン、アピキサバン、ダビガトラン、リバーロキサバン、エダキサバン、ワルファリン]についてメールでお問い合わせ |
